Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DT120 · 4 trials · 2 indications
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
| Arm | Type | Description |
|---|---|---|
| Arm 1 - Placebo | PLACEBO_COMPARATOR | A substance that is designed to have no therapeutic value |
| Arm 2 - 50µg DT120 | SHAM_COMPARATOR | A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
| Arm 3 - 100µg DT120 | EXPERIMENTAL | A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
| Arm 2 - 100µg DT120 | EXPERIMENTAL | A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | A substance that is designed to have no therapeutic value |
| DT120 | DRUG | A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depres...
DT120 is an investigational small molecule being developed for Generalized Anxiety Disorder and Major Depressive Disorder. It is currently in Phase 3 clinical trials for both psychiatric conditions.
DT120 is being developed by Definium Therapeutics, Inc., a biopharmaceutical company. Definium Therapeutics is advancing DT120 through Phase 3 clinical trials for Generalized Anxiety Disorder and Major Depressive Disorder.
DT120 is in Phase 3 clinical development. It is being studied in multiple Phase 3 trials for Generalized Anxiety Disorder and Major Depressive Disorder, and it remains investigational, not yet approved by regulatory authorities.
DT120 is being evaluated in four Phase 3 trials: NCT06741228 (Voyage) and NCT06809595 (Panorama) for Generalized Anxiety Disorder, and NCT06941844 (Emerge) and NCT07592689 (Ascend) for Major Depressive Disorder. All are randomized, double-blind, placebo-controlled studies.
DT120 is not the same as MM120. While both are being studied in Phase 3 trials for Generalized Anxiety Disorder, they are distinct investigational drugs. DT120 is developed by Definium Therapeutics, and the trials are separate.